Trial Government Bids & RFPs

The bid notice states that this acquisition will be competed as a 100% set aside for small business concerns, whereby only small business concerns will be eligible for award. The size standard for the associated NAICS code **** is 1,000 employees. A small business concern is defined as any business entity organized for profit with a place of business located in the United States or its outlying areas that makes a significant contribution to the U. S. economy.

The delivery requested for item **** is by 06 May 2026 and for item **** is by 06 May 2026. The bid notice states Delivery requested ship to by 06 May 2026.

The bid notice indicates that payment will be made by Wide Area Workflow (WAWF) as per DFARS clause 252. 232-7003. The notice states Method of payment is Wide Area Work Flow WAWF DFAR Clause **** Mar **** Electronic Submission of Payment Request and Receiving Reports is applicable to this solicitation.

The bid notice states that the award will be made to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the government, price and other factors considered, on the basis of lowest price, technically acceptable. The notice states Award will be made on the basis of lowest price, technically acceptable meeting or exceeding the acceptability standards for the noncost factor of technical capability.

The bid notice specifies that Electric boat is the only authorized manufacturer. No other sources are authorized.

The bid notice requires sample submission. It states If requested by the contracting officer, the offeror shall furnish sample units, in the number specified, to the contracting officer or to another location specified by the contracting officer, within 10 days after the contracting officer's request.

The deadline for submitting responses to this RFI/SSN is April 15, 2026, at 3:00 PM EDT.

BARDA anticipates awards will be made to multiple contractors with the best solutions and capabilities.

Mandatory eligibility criteria include data demonstrating a robust therapeutic mechanism of action applicable to severe disease due to influenza infection, demonstrated preclinical and/or clinical efficacy against severe disease due to viral respiratory infection, relevance to viral respiratory infection, rationale behind dose selection for a Phase 3 study, and feedback and concurrence from the FDA on the study design of a proposed or current Phase 3 study.